Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
HLA-DRA is one of the HLA class II alpha chain paralogues. Additionally we are shipping HLA Class II DR alpha Proteins (15) and HLA Class II DR alpha Kits (1) and many more products for this protein.
Showing 10 out of 133 products:
Human Polyclonal HLA-DRA Primary Antibody for EIA, FACS - ABIN453098
De Jager, Jia, Wang, de Bakker, Ottoboni, Aggarwal, Piccio, Raychaudhuri, Tran, Aubin, Briskin, Romano, Baranzini, McCauley, Pericak-Vance, Haines, Gibson, Naeglin, Uitdehaag, Matthews, Kappos, Polman, McArdle, Strachan, Evans, Cross, Daly, Compston, Sawc: Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. in Nature genetics 2009
The frequency of CD14 (show NDUFA2 Antibodies)(+)HLA-DR-/low MDSCs could be considered as a poor prognostic predictor in small-cell lung cancer (SCLC) and the elimination of MDSCs during medical interventions may improve the prognosis of SCLC patients.
This meta-analysis showed that the HLA-DRA rs3129882 A/G polymorphism was not a risk factor for Parkinson's disease in Chinese.
CD14 (show NDUFA2 Antibodies)+HLA-DR(-/low) cells were significantly increased in gastric cancer tissue and were shown to have a critical role in CD4 (show CD4 Antibodies)+T-cell immunosuppression.
No significant association was found for HLA-DRA/PARK18 (show EIF4G1 Antibodies) rs3129882 polymorphism and Parkinson's disease risk (meta-analysis).
Increased CD14 (show NDUFA2 Antibodies)+ monocytes with loss of HLA-DR expression were seen in patients with higher stage disease, more aggressive pathology, and in relapse or refractoriness to treatment.
HLA-DRA variants predict penicillin allergy in genome-wide fine-mapping genotyping
The effects of rs11248051 and rs1564282 variants of GAK (show GAK Antibodies), and the rs3129882 variant of HLA-DRA, were investigated in Parkinson's disease patients.
HLA-DOA (show HLA-DOA Antibodies), HLA-DRA, and HLA-DQA1 (show HLA-DQA2 Antibodies) associated with spontaneous autoimmunity
The SNP rs3129882 in intron 1 of HLA-DRA has been shown to be most robustly associated with the Parkinson's disease.
suggest that binding of MAM (show ATF7IP Antibodies) to HLA-DR leads to a conformational change in MAM (show ATF7IP Antibodies) structure allowing its interaction with TLR2 (show TLR2 Antibodies) and TLR4 (show TLR4 Antibodies) and a better recognition by T cells.
ALOX5AP (show ALOX5AP Antibodies), CPNE3 (show CPNE3 Antibodies), IL1R2 (show IL1R2 Antibodies), IL6 (show IL6 Antibodies), TLR2 (show TLR2 Antibodies), TLR4 (show TLR4 Antibodies), and THY1 (show THY1 Antibodies) were upregulated in blood polymorphonuclear cells in negative energy balance versus positive energy balance cows.
Four unique SSCP patterns were detected among 384 cattle from New Zealand and sequence analysis revealed that these SSCP patterns represent 4 DRA alleles; and 3 single nucleotide polymorphisms were detected in exon 2
HLA-DRA is one of the HLA class II alpha chain paralogues. This class II molecule is a heterodimer consisting of an alpha and a beta chain, both anchored in the membrane. It plays a central role in the immune system by presenting peptides derived from extracellular proteins. Class II molecules are expressed in antigen presenting cells (APC: B lymphocytes, dendritic cells, macrophages). The alpha chain is approximately 33-35 kDa and its gene contains 5 exons. Exon 1 encodes the leader peptide, exons 2 and 3 encode the two extracellular domains, and exon 4 encodes the transmembrane domain and the cytoplasmic tail. DRA does not have polymorphisms in the peptide binding part and acts as the sole alpha chain for DRB1, DRB3, DRB4 and DRB5.
major histocompatibility complex, class II, DR alpha
, HLA class II histocompatibility antigen, DR alpha chain
, MHC cell surface glycoprotein
, MHC class II antigen DRA
, histocompatibility antigen HLA-DR alpha
, MHC class II DRA
, MHC class II antigen